B cell depletion therapy in systemic lupus erythematosus: Long-term follow-up and predictors of response

Annals of the Rheumatic Diseases

Volumn 66, Issue 9, 2007, Pages 1259-1262

  Ng, Kristine P ^a   Cambridge, Geraldine ^a   Leandro, Maria J ^a   Edwards, Jonathan C W ^a   Ehrenstein, Michael ^a   Isenberg, David A ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Centre for Rheumatology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; MEPACRINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; WARFARIN;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; LOBAR PNEUMONIA; LONG TERM CARE; LOW DRUG DOSE; MALE; NEUTROPENIA; PATIENT ASSESSMENT; PRIORITY JOURNAL; SEPTICEMIA; SEROLOGY; SERUM SICKNESS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; BIOLOGICAL MARKERS; COMPLEMENT C3; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS INDICATORS; HUMANS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; RECURRENCE; RISK; TIME;

EID: 34548151122     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.067124     Document Type: Article

References (12)

1. Mason LJ, Isenberg DA. The pathogenesis of systemic lupus erythematosus. In: Davison AM, Cameron JS, Grunfela JP, Ponticelli C, Ritz E, Winearls CG, van Ypersele, eds. Oxford textbook of clinical nephrology. 3rd edn. Oxford: Oxford University Press, 2005:809-24.
2. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-7.
3. Sfikakis P, Boletis J, Tsokos G. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005;17:550-57.
4. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 2005;44:1542-5.
5. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
6. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.
7. Ng KP, Leandro MJ, Edwards JCW, Ehrenstein M, Cambridge G, Isenberg DA. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2006;65:942-5.
8. Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and anti-microbial antibody profiles. Arthritis Rheum 2006;54:3612-3622.
9. Salido M, Macarron P, Hernandez-Garcia C, D'Cruz DP, Khamashtha MA, Hughes GR. Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus. Lupus 2003;12:636-9.
10. McCune WJ, Miskella M. Immunosuppression drug therapy. In: Wallace DJ, Hahn BH, eds. Dubois lupus erythematosus. 6th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2002:1195-2018.
11. Tench CM, Isenberg DA. The variation in anti-ENA characteristics between different ethnic populations with systemic lupus erythematosus over a 10-year period. Lupus 2000;9:374-6.
12. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171:1581-7.